-
Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services
•
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco International Co., Ltd, a wholly-owned subsidiary of China Meheco Group Co., Ltd. The collaboration will focus on project cooperation and investment, leveraging the comprehensive advantages of both companies in information, knowledge, talent, products, and channels…
-
3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials
•
China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859 billion (USD 995.9 million), a 7.5% increase year-on-year (YOY). Net profits reached RMB 2.163 billion (USD 314 million), up 25.2% YOY. This marks a significant milestone in the company’s ongoing growth and expansion. Core Product…
-
Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000
•
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with compatriot firm TaiGen Biotechnology Co., Ltd. Under the terms of the agreement, Joincare will take exclusive development, manufacturing, and commercialization rights to TaiGen’s PA endonuclease inhibitor TG-1000, as well as its derivatives, in the Greater…
-
Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study
•
Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in 2018, has released interim data from the 16-week mark in the Phase III QUARTZ3 study. The study is assessing the efficacy of the JAK1 inhibitor ivarmacitinib in patients with moderate to severe atopic dermatitis (AD).…
-
Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms
•
Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical equipment firms to set up joint ventures (JVs) with majority stakes controlled by the state-owned company. This strategic move aims to enhance Sinopharm’s capabilities in the medical equipment sector. Radiotherapy and Imaging Joint VenturesSinopharm’s subsidiary,…
-
BeiGene Marks Topping Off of New Biologics Facility in New Jersey
•
China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the “topping off” of construction at its new biologics manufacturing and R&D facility in Hopewell, New Jersey. The last piece of structural steel was laid at the site, signaling that construction is now expected to be…
-
Roche Partners with China Resource Medicine to Promote Xofluza in China
•
Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource Medicine Commercial Holdings Ltd to jointly promote the anti-influenza drug Xofluza (baloxavir marboxil) in China. Under the agreement, Roche will continue to handle channel promotion for the drug in major hospitals, while CR Medicine Commercial…
-
Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination
•
China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme Inc. (NYSE: MRK) to assess the clinical effects of Jacobio’s CD73 monoclonal antibody (mAb) JAB-BX102 combined with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) in advanced solid tumors. No financial details were disclosed in the partnership agreement.…
-
Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis
•
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s F-652 has been cleared to start a Phase II clinical trial for a new indication by China’s National Medical Products Administration (NMPA). The trial will assess F-652 as a treatment for alcoholic hepatitis (AH). Mechanism…
-
BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392
•
Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with US-based biotech OncoC4, securing global development and commercialization rights to OncoC4’s anti-CTLA-4 antibody ONC-392. Under the terms of the agreement, BioNTech will pay OncoC4 USD 200 million upfront, with further undisclosed development and commercial milestone…
-
Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology
•
Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi in a Series C+ financing round. The round was led by Source Code Capital, with contributions from CCB Private Equity Investment, E-town Capital, Founder H Fund, and Lotus Lake Capital. The funds will be used…
-
L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development
•
Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series B financing round, led by Hongfeng Venture. Additional investors included Oriental Wisdom Capital, Zhongchuang Yongjian (Ningbo) Venture Capital, and existing investor Qiao Jing Capital. The funds will be directed towards Phase I clinical studies for…
-
T&L Biotechnology Secures RMB 100 Million in Series A Financing
•
Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB 100 million (USD 14.53 million) in a Series A financing round. The round was led by Harvest Capital and Fortune Capital, with participation from Zhiheng (Yantai) Entrepreneurship Service Center. The funds will be used to…
-
Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials
•
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its novel biologic product BIO-008. This marks a significant milestone in the development of the company’s innovative therapeutic biologic. Development and IndicationsBIO-008 is a monoclonal antibody…
-
Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing for SHR8028, an anti-inflammatory and immunomodulatory agent under development to treat dry eye, has been accepted for review by the National Medical Products Administration (NMPA) in China. Clinical Study and ResultsThe filing is based on…
-
LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China
•
China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD). The collaboration will focus on channel building, chronic disease compliance, member and private domain traffic management, and access to innovative drugs. Gilead aims to leverage LBX’s extensive network of over 10,000 drugstores, chronic disease and…
-
Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia
•
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has received Emergency Use Authorization (EUA) from Mongolia for its ReCOV, a recombinant COVID-19 vaccine co-developed by the Chinese Academy of Sciences. This authorization marks a significant milestone in the global distribution and accessibility of the…
-
WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials
•
China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording revenues of RMB 39.355 billion (USD 5.72 billion), a 71.8% increase year-on-year (YOY). Net profits also grew significantly, reaching RMB 8.814 billion (USD 1.28 billion), up 72.9% YOY. This marks a substantial milestone in the…
-
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
•
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its subsidiary Shandong Boan Biotechnology Co., Ltd’s BA1102, a biosimilar version of Amgen’s (NASDAQ: AMGN) Xgeva (denosumab), has been accepted for review by the Center for Drug Evaluation (CDE). Indications and Market ContextDenosumab is a monoclonal…
-
Bayer’s Nubeqa Receives Additional NMPA Approval for mHSPC Treatment-Fineline Info & Tech
•
German pharmaceutical giant Bayer AG (ETR: BAYN) has announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its drug Nubeqa (darolutamide). The drug, which was previously approved for use in non-metastatic castration-resistant prostate cancer (nmCRPC) in February 2021, can now be used to…
